Study title: A 30-Week, Forced-titration and Randomised, Crossover, Multicentre, Multinational Trial to Evaluate the Efficacy and Safety of rosuvastatin and Atorvastatin in Subjects with Homozygous Familial Hypercholesterolaemia (4522IL/0054): Full Report of the First 18 Weeks (forced-titration) and Last 12 Weeks of Treatment (crossover period) for Efficacy and for Safety
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nutritional and Metabolic Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ROSUVASTATIN CALCIUM | |||||
| ATC code: | |||||
| Document link: Study 4522IL0054_CSR Synopsis.pdf | |||||
| Document date: 2011-11-23 | |||||
| Study number: 4522IL0054 | |||||
| EudraCT number: | |||||
| Scope of study: | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |